{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:15:33Z","timestamp":1777043733217,"version":"3.51.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Although anti\u2013programmed cell death molecule-1 (PD-1)\/PD-1 ligand therapy has achieved remarkable success in oncology field, the low response rate and lack of accurate prognostic biomarker identifying benefiting patients remain unresolved challenges. This study developed a PD-1 targeting radiotracer <jats:sup>124<\/jats:sup>I-labeled toripalimab (<jats:sup>124<\/jats:sup>I-JS001) for clinical PET imaging and evaluated its biodistribution, safety, and dosimetry in human.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with melanoma or urologic cancer confirmed by pathology were enrolled. <jats:sup>124<\/jats:sup>I-JS001 PET\/CT and PET\/MR were performed with or without coinjection of 5 mg unlabeled JS001, and <jats:sup>18<\/jats:sup>F-FDG PET was undertaken within 1 week.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eight melanoma and 3 urologic cancer patients were enrolled. No adverse events were noticed during the whole examination after the injection of <jats:sup>124<\/jats:sup>I-JS001 and an acceptable dosimetry of 0.236 mSv\/MBq was found. <jats:sup>124<\/jats:sup>I-JS001 PET\/CT showed high uptake in spleen and liver and slight uptake in bone marrow and lung. All primary and metastatic tumor lesions in 11 patients demonstrated different levels of uptake of <jats:sup>124<\/jats:sup>I-JS001 with SUVmax ranging from 0.2 to 4.7. With coinjection of unlabeled JS001, the uptake in spleen was reduced significantly (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05), whereas tumor uptake and tumor background ratio increased significantly (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). Four patients undertook regional <jats:sup>124<\/jats:sup>I-JS001 PET\/MR. All tumor lesions were detected effectively with abnormal MR signal on PET\/MR, whereas PET\/MR detected liver lesions more sensitively than PET\/CT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The first-in-human study demonstrated <jats:sup>124<\/jats:sup>I-JS001 was a safe tracer for PET with acceptable dosimetry, and the PET\/CT results showed a favorable biodistribution. PET\/MR could detect liver lesions more sensitively than PET\/CT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003520","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T05:22:41Z","timestamp":1611897761000},"page":"382-388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab"],"prefix":"10.1097","volume":"46","author":[{"given":"Shujing","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Ding","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangxi","family":"Meng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Ding","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yao","sequence":"additional","affiliation":[{"name":"Shanghai Junshi Biosciences Co Ltd, Shanghai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","year":"2017","journal-title":"Front Pharmacol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and clinical activity with an anti\u2013PD-1 antibody JS001 in advanced melanoma or urologic cancer patients","volume":"12","year":"2019","journal-title":"J Hematol Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/annonc\/mdx305","article-title":"The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3390\/cancers11101554","article-title":"Predictive factors for response to PD-1\/PD-L1 checkpoint inhibition in the field of hepatocellular carcinoma: current status and challenges","volume":"11","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ijc.32744","article-title":"Association of PD-L1 expression status with the efficacy of PD-1\/PD-L1 inhibitors and overall survival in solid tumours: a systematic review and meta-analysis","volume":"147","year":"2020","journal-title":"Int J Cancer"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","year":"2018","journal-title":"Mol Cancer"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432","volume":"30","year":"2019","journal-title":"Ann Oncol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.7150\/thno.24762","article-title":"Noninvasive imaging of the PD-1: PD-L1 immune checkpoint: embracing nuclear medicine for the benefit of personalized immunotherapy","volume":"8","year":"2018","journal-title":"Theranostics"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/0008-5472.CAN-14-3477","article-title":"Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti\u2013PD-L1 antibodies","volume":"75","year":"2015","journal-title":"Cancer Res"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1021\/acs.bioconjchem.5b00318","article-title":"Novel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes","volume":"26","year":"2015","journal-title":"Bioconjug Chem"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.7150\/thno.15253","article-title":"High-resolution PET imaging with therapeutic antibody-based PD-1\/PD-L1 checkpoint tracers","volume":"6","year":"2016","journal-title":"Theranostics"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non\u2013small-cell lung cancer","volume":"9","year":"2018","journal-title":"Nat Commun"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/aps.2016.161","article-title":"Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody","volume":"38","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bmcl.2019.06.019","article-title":"Development of 99mTc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine","volume":"29","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.apsb.2020.02.004","article-title":"Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice","volume":"10","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2967\/jnumed.117.207431","article-title":"Biodistribution and radiation dosimetry of 124I-DPA-713, a PET radiotracer for macrophage-associated inflammation","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-immunol-032712-100019","article-title":"T cell\u2013mediated host immune defenses in the lung","volume":"31","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2967\/jnumed.117.193268","article-title":"Imaging of programmed cell death ligand 1: impact of protein concentration on distribution of anti\u2013PD-L1 SPECT agents in an immunocompetent murine model of melanoma","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"117093","DOI":"10.1016\/j.lfs.2019.117093","article-title":"Anti\u2013PD-1 immunotherapy in advanced metastatic melanoma: state of the art and future challenges","volume":"240","year":"2020","journal-title":"Life Sci"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"10215","DOI":"10.18632\/oncotarget.7143","article-title":"A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2967\/jnumed.111.098608","article-title":"First clinical experience with integrated whole-body PET\/MR: comparison to PET\/CT in patients with oncologic diagnoses","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"e0206573","DOI":"10.1371\/journal.pone.0206573","article-title":"Towards fast whole-body PET\/MR: investigation of PET image quality versus reduced PET acquisition times","volume":"13","year":"2018","journal-title":"PLoS One"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.mric.2016.12.006","article-title":"Practical considerations for clinical PET\/MR imaging","volume":"25","year":"2017","journal-title":"Magn Reson Imaging Clin N Am"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:03:19Z","timestamp":1750539799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003520"}},"subtitle":["A Pilot Clinical Translation Study"],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003520","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}